Compare WHLR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHLR | ONCO |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.3M |
| IPO Year | 2012 | 2022 |
| Metric | WHLR | ONCO |
|---|---|---|
| Price | $1.95 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 55.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 61.36 | N/A |
| Revenue | ★ $101,834,000.00 | $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $1.37 |
| 52 Week High | $6,719.86 | $88.40 |
| Indicator | WHLR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 43.69 |
| Support Level | $1.58 | $1.52 |
| Resistance Level | $2.06 | $1.71 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 25.53 | 57.89 |
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.